The 2022 European Society of Cardiology risk assessment tool accurately predicts survival in patients with systemic sclerosis-associated pulmonary arterial hypertension. The tool, based on WHO functional class, serum NT-proBNP, and six-minute walk distance, stratifies patients into low, intermediate, and high-risk categories. The study included 260 patients and found that a higher risk score was associated with increased mortality. It suggests that regular risk assessments can guide treatment decisions and improve outcomes for patients with SSc-PAH. The tool provides accessible means for rheumatologists to predict outcomes and adjust PAH-specific therapy according to the guidelines.
Source link
ESC scoring tool predicts survival in SSc-associated pulmonary arterial hypertension
